Salivary Antipyrine Kinetics in Hepatic and Renal Disease and in Patients on Anticonvulsant Therapy

Publisher Website
Google Scholar
Abstract
The effects in man of liver disease, renal failure and hepatic microsomal enzyme induction on the elimination kinetics of antipyrine in salive was examined. Antipyrine (10 mg/kg) was given orally and assayed in saliva by GLC. The mean antipyrine half-life from saliva in 9 epileptics receiving long term anticonvulsant drug therapy (6 h .+-. 0.9 SEM) [standard error of the mean] was significantly shorter than in 20 normal healthy volunteers (10.7 .+-. 0.6). Therapy included phenytoin and phenobarbitone, 2 drugs known to induce hepatic microsomal enzymes. Five subjects with chronic renal failure exhibited no significant difference in salivary antipyrine half-live (11.7 .+-. 1.9) compared to the control group, whereas 6 subjects with chronic liver disease and impaired hepatic function had significantly increased half-life values (42.4 .+-. 10). Differences in the activity of hepatic microsomal enzymes appear to be reflected by changes in salivary antipyrine elimination kinetics. Chronic renal failure appeared to have no effect on the function of these enzymes.
Keywords